Literature DB >> 6315329

[Effect of cimetidine and ranitidine on the pharmacokinetics and anti-hypertensive effect of nifedipine].

W Kirch, H D Janisch, H Heidemann, K Rämsch, E E Ohnhaus.   

Abstract

Simultaneous administration of cimetidine and nifedipine to six healthy volunteers produced an about 80% rise in maximal plasma levels and the area under the plasma level-time curve of nifedipine compared with results on nifedipine administration alone (P less than 0.05). After treatment for one week with 4 X 10 mg nifedipine daily and 3 X 200 mg cimetidine daily and 400 mg at night plasma level peaks of nifedipine averaged 87.7 +/- 19.1 ng/ml, while after 4 X 10 mg nifedipine alone they were only 46.1 +/- 10.6 ng/ml. Ranitidine produced an approximately 25%, nonsignificant, rise in plasma level-time curve and peak plasma levels of nifedipine. Seven hypertensives (WHO stage I and II) had a mean arterial blood pressure level of 127 +/- 2.5 mm Hg after two-week placebo administration, and of 109 +/- 2.38 mm Hg after four weeks of nifedipine alone at 4 X 10 mg daily (P less than 0.01). After additional administration of 1 g cimetidine daily for two weeks the mean blood pressure fell significantly to 95 +/- 3.1 mm Hg (P = 0.02), while blood pressure fell to 103 +/- 3.88 mm Hg after two weeks of additional administration of 300 mg ranitidine daily, a fall which was not significant (P greater than 0.05). The interaction of nifedipine and cimetidine is thus of clinical significance because of its pharmacodynamic effect.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6315329     DOI: 10.1055/s-2008-1069821

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  15 in total

Review 1.  Clinical relevance of cimetidine drug interactions.

Authors:  A F Shinn
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

2.  Influence of the H2-receptor antagonists cimetidine and ranitidine on the pharmacokinetics of nimodipine in healthy volunteers.

Authors:  W Mück; W Wingender; M Seiberling; E Woelke; K D Rämsch; J Kuhlmann
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 3.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

Review 4.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

5.  Factors affecting the pharmacokinetics of nifedipine.

Authors:  A G Renwick; J Le Vie; V F Challenor; D G Waller; B Gruchy; C F George
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 6.  Calcium antagonists. Drug interactions of clinical significance.

Authors:  T Rosenthal; D Ezra
Journal:  Drug Saf       Date:  1995-09       Impact factor: 5.606

Review 7.  Safety of acid-suppressing drugs.

Authors:  R A Smallwood; R G Berlin; N Castagnoli; H P Festen; C J Hawkey; S K Lam; M J Langman; P Lundborg; A Parkinson
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

8.  The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine.

Authors:  A Khan; S J Langley; F G Mullins; J S Dixon; S Toon
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

Review 9.  Pharmacokinetic interactions of cimetidine 1987.

Authors:  A Somogyi; M Muirhead
Journal:  Clin Pharmacokinet       Date:  1987-05       Impact factor: 6.447

Review 10.  Interactions and non-interactions with ranitidine.

Authors:  W Kirch; H Hoensch; H D Janisch
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.